Recurrent Myelodysplastic/Myeloproliferative Neoplasm (DBCOND0130506)
Identifiers
- Synonyms
- Not Available
Associated Data
- Indicated Drugs and Targets
- Not Available
- Clinical Trials
Identifier Title Drug(s) Purpose Phase Status NCT06523556 Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia treatment 1 / 2 recruiting NCT04140487 Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm treatment 1 / 2 recruiting NCT03878524 Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial - Abemaciclib
- Abiraterone
- Afatinib
- Albumin human
- Avobenzone
- Bevacizumab
- Bicalutamide
- Bortezomib
- Bortezomib D-mannitol
- Cabazitaxel
- Cabozantinib
- Capecitabine
- Carboplatin
- Celecoxib
- Cobimetinib
- Copanlisib
- Dabrafenib
- Dacomitinib
- Darolutamide
- Dasatinib
- Daunorubicin
- Doxorubicin
- Durvalumab
- Enasidenib
- Entrectinib
- Enzalutamide
- Erlotinib
- Everolimus
- Fluorouracil
- Idelalisib
- Imatinib
- Ipilimumab
- Lenvatinib
- Leucovorin
- Lorlatinib
- Losartan
- Neratinib
- Nivolumab
- Octinoxate
- Olaparib
- Oxaliplatin
- Paclitaxel
- Palbociclib
- Panobinostat
- Pembrolizumab
- Pertuzumab
- Ponatinib
- Regorafenib
- Ruxolitinib
- Sirolimus
- Sorafenib
- Sunitinib
- Trametinib
- Trastuzumab emtansine
- Tretinoin
- Vemurafenib
- Venetoclax
- Vismodegib
- Vorinostat
treatment 1 terminated NCT03630991 Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy treatment 1 recruiting